NX 1607

Key Product Details

Product Description

NX 1607 (Cbl-b-IN-3) is an inhibitor of CBL-B (Casitas B-lineage lymphoma proto-oncogene B), a RING-type E3 ubiquitin ligase. NX 1607 acts as an intramolecular glue. In vitro, NX 1607 activates MAPK/ERK signaling pathway and enhances T-cell activation in primary T cells and Jurkat T cells. In vivo, NX 1607 decreases tumor growth in cell lymphoma models. NX 1607 is orally bioavailable.

Licensing Information

Sold under license from Nurix Therapeutics

Product Specifications for NX 1607

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for NX 1607

The following data is based on the product molecular weight 537.63.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.86 mL	9.30 mL	18.60 mL
5 mM	0.37 mL	1.86 mL	3.72 mL
10 mM	0.19 mL	0.93 mL	1.86 mL
50 mM	0.04 mL	0.19 mL	0.37 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Zhu Cbl-b inhibitor NX-1607 activates MAPK/ERK signaling pathway and enhances T-cell activation. J.Immunother.Cancer 2025 PMID: 40447319

Product Documents for NX 1607